Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update
May 17, 2021 08:00 ET
|
Vincerx Pharma, Inc.
Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 First patient in Phase 1b Study of VIP152 in...
Vincerx Pharma Announces Completion of Public Warrant Redemption
May 06, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced the completion of its redemption event with respect to its outstanding public...
Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome
April 20, 2021 08:00 ET
|
Vincerx Pharma, Inc.
Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021 Vincerx’s second clinical program for potential best-in-class CDK9...
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021
April 10, 2021 08:31 ET
|
Vincerx Pharma, Inc.
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022 PALO ALTO, Calif., April 10, 2021 (GLOBE NEWSWIRE)...
Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematologic and Solid Tumors
April 07, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Announces Redemption of Public Warrants
April 05, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced that it will redeem all of its outstanding public warrants (the “Public...
Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline
April 01, 2021 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
March 23, 2021 08:00 ET
|
Vincerx Pharma, Inc.
License agreement with Bayer AG secures oncology portfolio including clinical-stage PTEFb/CDK9 inhibitor with encouraging Phase 1 activity Successful completion of business combination transaction,...
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
March 10, 2021 16:32 ET
|
Vincerx, Inc.
PALO ALTO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Strengthens Management Team with Three New Appointments
March 02, 2021 08:00 ET
|
Vincerx, Inc.
PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...